Closing regulatory gaps: new ground rules for platelet-rich plasma

Area of Science:

• Biomedical Regulation
• Regenerative Medicine

Background:

• Platelet-rich plasma (PRP) is increasingly used in various medical applications.
• Existing regulatory frameworks for PRP are inconsistent globally.
• The Spanish Agency of Medicines and Medical Devices (AEMPS) has addressed this gap.

Purpose of the Study:

• To outline the new regulatory framework for platelet-rich plasma (PRP) in Spain.
• To identify challenges in adapting PRP use to new safety and efficacy standards.

Main Methods:

• Analysis of the AEMPS comprehensive report and resolution on PRP.
• Review of current global regulatory approaches to PRP.

Main Results:

• Spain has established the first comprehensive regulatory framework for PRP as a medicinal product.
• The heterogeneity of PRP products presents significant regulatory challenges.
• Divergent international regulations for PRP products were identified.

Conclusions:

• The new Spanish regulation for PRP introduces novel challenges for product standardization and compliance.
• Harmonizing global PRP regulations remains a critical issue for ensuring consistent safety and efficacy.